Literature DB >> 26622711

Expression of TYMS in lymph node metastasis from low-grade glioma.

Bingqian Ding1, Ming Gao1, Zhenjiang Li1, Chenyang Xu1, Shaokang Fan1, Weiya He2.   

Abstract

The aim of the present study was to investigate the expression of thymidylate synthase (TYMS) in the primary foci and metastatic lymph nodes of low-grade glioma, and to analyze the function of TYMS in the lymph node metastases from low-grade glioma. The study included 93 cases of surgically resected and pathologically confirmed low-grade glioma, form patients treated at Huaihe Hospital of Henan University (Kaifeng, China). The following clinical data was obtained from each patient: Gender, age, subjective symptoms (dizziness, headache, a feeling of pressure in the head, etc.), site of disease, tumor type, pathological stage, degree of differentiation and lymph node involvement. The surgically resected gliomas and dissected cervical lymph nodes were immunohistochemically stained, and DNA was extracted from the tumor and lymph node tissues samples for polymerase chain reaction sequencing and amplification. The expression of TYMS in the primary foci and metastatic lymph nodes of low-grade glioma was examined. Additionally, the association between pathological features and the postoperative survival rate of the patients was analyzed. The primary lesions of all 93 cases exhibited positive TYMS expression and 43/157 (27.39%) lymph nodes exhibited positive TYMS expression. Factors that significantly influenced the postoperative survival rate of the patients, included the metastasis of the cervical lymph nodes (P<0.01), the number of dissected cervical lymph nodes (P<0.01) and the degree of differentiation (P<0.05). The metastasis of the cervical lymph nodes was the only independent risk factor affecting postoperative disease-free survival. The risk of recurrence in patients with metastasis of the cervical lymph nodes was 6.3-fold higher than in those without metastasis (P<0.01). Thus, the results of the present study provide a theoretical basis for accurately predicting the prognosis of patients with low-grade malignant brain glioma, reducing the conjecture involved in selecting postoperative treatment strategies and improving therapeutic efficacy.

Entities:  

Keywords:  brain glioma; lymphatic metastasis; survival rate; thymidylate synthase

Year:  2015        PMID: 26622711      PMCID: PMC4533609          DOI: 10.3892/ol.2015.3419

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  25 in total

1.  Prospective randomized trial of low- versus high-dose radiation therapy in adults with supratentorial low-grade glioma: initial report of a North Central Cancer Treatment Group/Radiation Therapy Oncology Group/Eastern Cooperative Oncology Group study.

Authors:  E Shaw; R Arusell; B Scheithauer; J O'Fallon; B O'Neill; R Dinapoli; D Nelson; J Earle; C Jones; T Cascino; D Nichols; R Ivnik; R Hellman; W Curran; R Abrams
Journal:  J Clin Oncol       Date:  2002-05-01       Impact factor: 44.544

2.  Randomized phase II study of temozolomide and radiotherapy compared with radiotherapy alone in newly diagnosed glioblastoma multiforme.

Authors:  Helen Athanassiou; Maria Synodinou; Evagelos Maragoudakis; Mihalis Paraskevaidis; Cosmas Verigos; Despina Misailidou; Dosia Antonadou; George Saris; Konstantinos Beroukas; Pantelis Karageorgis
Journal:  J Clin Oncol       Date:  2005-04-01       Impact factor: 44.544

3.  Role of the F-box protein Skp2 in lymphomagenesis.

Authors:  E Latres; R Chiarle; B A Schulman; N P Pavletich; A Pellicer; G Inghirami; M Pagano
Journal:  Proc Natl Acad Sci U S A       Date:  2001-02-20       Impact factor: 11.205

4.  Microfoci of malignant progression in diffuse low-grade gliomas: towards the creation of an intermediate grade in glioma classification?

Authors:  Zoé Pedeutour-Braccini; Fanny Burel-Vandenbos; Catherine Gozé; Coralie Roger; Audrey Bazin; Valérie Costes-Martineau; Hugues Duffau; Valérie Rigau
Journal:  Virchows Arch       Date:  2015-01-21       Impact factor: 4.064

5.  High expression of S-phase kinase-interacting protein 2, human F-box protein, correlates with poor prognosis in oral squamous cell carcinomas.

Authors:  Y Kudo; S Kitajima; S Sato; M Miyauchi; I Ogawa; T Takata
Journal:  Cancer Res       Date:  2001-10-01       Impact factor: 12.701

6.  The prognostic value of overexpression of Skp2 mRNA in non-small cell lung cancer.

Authors:  Iwao Takanami
Journal:  Oncol Rep       Date:  2005-04       Impact factor: 3.906

7.  The 2007 WHO Classification of Nervous System Tumors: newly recognized members of the mixed glioneuronal group.

Authors:  Marc K Rosenblum
Journal:  Brain Pathol       Date:  2007-07       Impact factor: 6.508

8.  Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.

Authors:  Roger Stupp; Monika E Hegi; Warren P Mason; Martin J van den Bent; Martin J B Taphoorn; Robert C Janzer; Samuel K Ludwin; Anouk Allgeier; Barbara Fisher; Karl Belanger; Peter Hau; Alba A Brandes; Johanna Gijtenbeek; Christine Marosi; Charles J Vecht; Karima Mokhtari; Pieter Wesseling; Salvador Villa; Elizabeth Eisenhauer; Thierry Gorlia; Michael Weller; Denis Lacombe; J Gregory Cairncross; René-Olivier Mirimanoff
Journal:  Lancet Oncol       Date:  2009-03-09       Impact factor: 41.316

Review 9.  Temozolomide for high grade glioma.

Authors:  Michael G Hart; Robert Grant; Ruth Garside; Gabriel Rogers; Margaret Somerville; Ken Stein
Journal:  Cochrane Database Syst Rev       Date:  2008-10-08

10.  Inhibition of NF-κB signaling ablates the invasive phenotype of glioblastoma.

Authors:  Mike-Andrew Westhoff; Shaoxia Zhou; Lisa Nonnenmacher; Georg Karpel-Massler; Claudia Jennewein; Matthias Schneider; Marc-Eric Halatsch; Neil O Carragher; Bernd Baumann; Alexander Krause; Thomas Simmet; Max G Bachem; Christian R Wirtz; Klaus-Michael Debatin
Journal:  Mol Cancer Res       Date:  2013-10-21       Impact factor: 5.852

View more
  6 in total

1.  Identification of TYMS as a promoting factor of retroperitoneal liposarcoma progression: Bioinformatics analysis and biological evidence.

Authors:  Sha Zhang; Liang Yan; Can Cui; Zhen Wang; Jianhui Wu; Min Zhao; Bin Dong; Xiaoya Guan; Xiuyun Tian; Chunyi Hao
Journal:  Oncol Rep       Date:  2020-06-05       Impact factor: 3.906

2.  Proteomics of Sentinel Lymph Nodes in Early Breast Cancer for Identification of Thymidylate Synthase as a Potential Biomarker to Flag Metastasis: A Preliminary Study.

Authors:  Sheetal Pathania; Mohd Imran Khan; Abhishek Kumar; Ashish Kumar Gupta; Komal Rani; Tanvi Ramesh Parashar; Jnaneshwari Jayaram; Piyush Ranjan Mishra; Anurag Srivastava; Sandeep Mathur; Smriti Hari; Gururao Hariprasad
Journal:  Cancer Manag Res       Date:  2020-06-23       Impact factor: 3.989

3.  Association Between Genetic Polymorphisms In TYMS And Glioma Risk In Chinese Patients: A Case-Control Study.

Authors:  Li Yao; Linghui Zhou; Yujiao Deng; Yi Zheng; Pengtao Yang; Meng Wang; Shanshan Dong; Qian Hao; Peng Xu; Na Li; Ying Wu; Zhen Zhai; Lijuan Lyu; Zhijun Dai
Journal:  Onco Targets Ther       Date:  2019-10-07       Impact factor: 4.147

4.  Blocking COX-2 induces apoptosis and inhibits cell proliferation via the Akt/survivin- and Akt/ID3 pathway in low-grade-glioma.

Authors:  Aya Sato; Yoshifumi Mizobuchi; Kohei Nakajima; Kenji Shono; Toshitaka Fujihara; Teruyoshi Kageji; Keiko Kitazato; Kazuhito Matsuzaki; Hideo Mure; Kazuyuki Kuwayama; Akiko Sumi; Hideyuki Saya; Oltea Sampetrean; Shinji Nagahirao
Journal:  J Neurooncol       Date:  2017-03-10       Impact factor: 4.130

5.  FOXM1-induced TYMS upregulation promotes the progression of hepatocellular carcinoma.

Authors:  Liang Wang; Caiyan Shi; Jie Yu; Yilin Xu
Journal:  Cancer Cell Int       Date:  2022-01-29       Impact factor: 5.722

6.  Expression of Carboxypeptidase A3 and Tryptase as Markers for Lymph Node Metastasis of Canine Cutaneous Mast Cell Tumors.

Authors:  Tuddow Thaiwong; Juliana V Cirillo; Jane Heller; Matti Kiupel
Journal:  Front Vet Sci       Date:  2022-02-14
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.